CONTEXT:  Peer reviewed retrospective study of a triple oral combination therapy in PAH | Japan only data.  IMPACT:  medium READ TIME:  2 mins Quality Level Mean [1 – 10]:  8 1. “Triple oral combination therapy with macitentan, riociguat, and selexipag may be a promising strategy to treat patients with low/intermediate-risk pulmonary arterial hypertension (PAH), and possibly even patients with high-risk PAH, according to a study published in Therapeutic Advances in Respiratory Disease .”  2. “The researchers conducted a retrospective study in Keio University Hospital in Japan evaluating patients with PAH who received the triple oral combination therapy of macitentan, riociguat, and selexipag.”  3. “The study found that the combination therapy improved the hemodynamics, right ventricular function, and clinical function for patients.”  4. ““In particular, this triple oral combination therapy can be a promising therapeutic strategy in patients with low/intermediate risk and possibly even in half of patients with high risk,” the authors concluded.”  Source URL: https://www.ajmc.com/view/real-world-study-finds-oral-combination-therapy-of-macitentan-riociguat-and-selexipag-effective-in-pah